Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30113% above fair value
$43.24+0.84 (+1.98%)
Close on Nov 11, 2026Market cap $50.39BP/E 72.1Yield –
Teva Pharmaceutical Industries enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Teva Pharmaceutical Industries's enterprise value was $50.46B on Nov 10, 2026, against $28.87B a year earlier. Over the last 5 years it ranged from $7.62B to $50.46B, with a median of $16.03B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 10, 2026 | $50.46B | +49.0% |
| 2025 | Dec 31, 2025 | $33.86B | +38.6% |
| 2024 | Dec 31, 2024 | $24.42B | +112.1% |
| 2023 | Dec 29, 2023 | $11.51B | +0.9% |
| 2022 | Dec 30, 2022 | $11.41B | +8.7% |
| 2021 | Dec 31, 2021 | $10.50B | -11.4% |
| 2020 | Dec 31, 2020 | $11.85B | -12.6% |
| 2019 | Dec 31, 2019 | $13.55B | -24.3% |
| 2018 | Dec 31, 2018 | $17.90B | -48.8% |
| 2017 | Jan 31, 2017 | $34.94B | -6.9% |
| 2016 | Dec 30, 2016 | $37.55B | -35.1% |
| 2015 | Dec 31, 2015 | $57.85B | +16.8% |
| 2014 | Dec 31, 2014 | $49.52B | +38.7% |
| 2013 | Dec 31, 2013 | $35.72B | +11.5% |
| 2012 | Dec 31, 2012 | $32.02B | -17.1% |
| 2011 | Dec 30, 2011 | $38.65B | -21.0% |
| 2010 | Dec 31, 2010 | $48.95B | -4.7% |
| 2009 | Dec 31, 2009 | $51.36B | – |
See a number that looks wrong?